<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452307</url>
  </required_header>
  <id_info>
    <org_study_id>167/2003</org_study_id>
    <nct_id>NCT02452307</nct_id>
  </id_info>
  <brief_title>Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy</brief_title>
  <official_title>Prospective Randomized Trial of Peptide-specific Vaccination in HLA-A*02 Positive Prostate Carcinoma Patients With Biochemical Recurrence After Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the prostate-specific antigen (PSA) response in HLA-A*02 positive
      patients with biochemical recurrence after radical prostatectomy treated with a
      prostate-specific peptide vaccine in combination with different immune-adjuvants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a biochemical recurrence after initial therapy can be included.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Immune Response at day 70</measure>
    <time_frame>Days 0-70</time_frame>
    <description>Immune Response, as measured by the change of in vitro and in vivo T cell response from baseline at day 0 to day 70</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Days 0-420</time_frame>
    <description>Tolerability, as measured by number of Participants with Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>Months 0-60</time_frame>
    <description>Treatment response, from date of randomization until the date of first documented progression as measured by PSA-value</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Peptide vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peptide vaccine + GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Granulocyte macrophage colony stimulating factor (GM-CSF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peptide vaccine + local hyperthermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with local hyperthermia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peptide vaccine + Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Imiquimod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peptide vaccine + mRNA/Protamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with mRNA/Protamin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peptide vaccine</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>Peptide vaccine</arm_group_label>
    <arm_group_label>Peptide vaccine + GM-CSF</arm_group_label>
    <arm_group_label>Peptide vaccine + local hyperthermia</arm_group_label>
    <arm_group_label>Peptide vaccine + Imiquimod</arm_group_label>
    <arm_group_label>Peptide vaccine + mRNA/Protamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montanide ISA-51</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>Peptide vaccine</arm_group_label>
    <arm_group_label>Peptide vaccine + GM-CSF</arm_group_label>
    <arm_group_label>Peptide vaccine + local hyperthermia</arm_group_label>
    <arm_group_label>Peptide vaccine + Imiquimod</arm_group_label>
    <arm_group_label>Peptide vaccine + mRNA/Protamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte macrophage colony stimulating factor (GM-CSF)</intervention_name>
    <description>intradermal</description>
    <arm_group_label>Peptide vaccine + GM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>epicutaneous</description>
    <arm_group_label>Peptide vaccine + Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mRNA</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>Peptide vaccine + mRNA/Protamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Protamin</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>Peptide vaccine + mRNA/Protamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>local hyperthermia</intervention_name>
    <arm_group_label>Peptide vaccine + local hyperthermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biochemical recurrence after Radical Prostatectomy

          -  no clinical metastases in CT or bone scan

          -  HLA-Type: HLA-A*02 positive

          -  Karnofsky-Performance-Index &gt;70

          -  Age &gt;45 / &lt;80 years

          -  no prior or ongoing hormonal therapy

          -  no ongoing radiation therapy

          -  Serum-Creatinine &lt;2mg/dl; Bilirubin: &lt;2gm/dl

          -  no history of allergy or chronic obstructive lung disease (COLD)

        Exclusion Criteria:

          -  Patients unable to consent

          -  Karnofsky-Performance-Index &lt;70

          -  known allergy or COLD

          -  presence of secondary malignancy

          -  prior or ongoing hormonal treatment

          -  ongoing radiotherapy

          -  immunosuppressive medication

          -  seizure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnulf Stenzl, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, University of Tuebingen</affiliation>
  </overall_official>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

